EXTENDED REPORT

Association of the oestrogen receptor α gene polymorphisms with disease onset in systemic lupus erythematosus

Y J Lee, K S Shin, S W Kang, C K Lee, B Yoo, H S Cha, E M Koh, S J Yoon, J Lee

Ann Rheum Dis 2004;63:1244–1249. doi: 10.1136/ard.2003.012583

See end of article for authors' affiliations

Correspondence to:
Dr K S Shin, Department of Paediatrics, College of Medicine, Cheju National University, 1 Ara 1(il)-dong, Jeju, Jeju-do 690-756, Korea;
kyungsue@cheju.ac.kr

Accepted
19 November 2003

Objective: To evaluate the genetic influence of *PvuII* and *XbaI* polymorphisms of oestrogen receptor α (*OR α*) in patients with systemic lupus erythematosus (SLE) in Korea.

Methods: Genomic DNA from 268 female controls and 137 female SLE patients (41 childhood onset and 96 adult onset) were analysed using *PvuII* and *XbaI* restriction fragment length polymorphism. Comparison of the frequencies of alleles and genotypes was made in control and patient groups and in childhood onset and adult onset SLE subgroups.

Results: Although the Pp genotype occurred more often in SLE patients than in controls ($p_c=0.017$), *OR α* genotype distributions of adult onset SLE did not differ significantly from controls. The PP, Pp, and xx genotypes occurred less often in childhood onset SLE ($p_c=0.0045$, 0.0498, and 0.0255, respectively) than in controls. Additionally, the PP genotype was less common in childhood onset than in adult onset SLE ($p_c=0.016$). SLE patients with the PP genotypes were older at disease onset than those with the other genotypes ($p=0.001$). Patients with the Xx genotype had an earlier onset of SLE than those with the xx genotype ($p=0.025$). The frequency of the combined ppXx genotype was greater in childhood onset SLE than in controls ($p_c=0.0009$) or adult onset SLE ($p_c=0.027$). The same trend was supported by subgroup analyses according to age at menarche and logistic multivariate analyses.

Conclusions: *OR α* polymorphisms are significantly associated with the age at disease onset in Koreans with SLE.

Systemic lupus erythematosus (SLE) is an idiopathic systemic inflammatory disease with diverse manifestations. Although the aetiopathology of SLE is not clearly understood, sex hormones are considered to affect the pathogenic mechanism. Epidemiologically, a female predominance is consistently demonstrated—about 90% of adult SLE patients are female. The peak incidence of SLE occurs in the reproductive period, and a postmenopausal onset of SLE is relatively uncommon.¹

Experimentally, the progression of lupus and mortality are different in female and male mice, and exogenous oestrogen reduces longevity and accelerates nephritis in the NZB/NZW lupus model.² Oestradiol stimulates the production of autoantibody to dsDNA in peripheral blood mononuclear cells (PBMC),³ and decreases apoptosis of PBMC from SLE patients.⁴ In addition, oestrogen augments SS-A/Ro and SS-B/La antigen expression on the cell surface of human keratinocytes,⁵ and stimulates macrophages from SLE patient to produce IL-10, the levels of which increase in sera of SLE patients.⁶ Recently, it was reported that oestrogen increased calcineurin and CD40 ligand in SLE T cells.⁷ Some epidemiological studies have suggested that women taking postmenopausal hormone replacement or oral contraceptives could be at increased risk of developing SLE.^{8–9}

Oestrogen acts through two nuclear receptors—*OR α* (oestrogen receptor α) and *OR β* —and the activity of these receptors may affect the actions of oestrogen. *PvuII* and *XbaI* polymorphisms of *OR α* have been studied in many diseases, and there are reports that these polymorphisms are associated with breast cancer, endometrial cancer, generalised osteoarthritis, osteoporosis, and the effects of oestrogen replacement on lipid metabolism.^{10–16}

There are few studies of *OR α* polymorphisms in SLE,^{17–18} and *OR α* polymorphism in childhood onset SLE has never

been reported. We hypothesised that *OR α* polymorphisms are associated with SLE, and we analysed *PvuII* and *XbaI* restriction fragment length polymorphisms (RFLP) of *OR α* in patients with childhood and adult onset of SLE in Korea.

METHODS

Study subjects

We recruited 137 female patients with SLE (mean age, 23.2 years (range 3 to 67); 41 with age at onset <16 years) and 268 sex and age matched controls (mean age, 31.4 years (range 3 to 70); 48 aged <16 years). Healthy adult controls were enrolled from subjects attending routine medical check ups; child controls were children admitted for elective surgery or transient acute infection. There was no significant difference in the allele and genotype frequencies of *PvuII* or *XbaI* RFLPs between adult and child control groups. SLE was diagnosed according to the criteria proposed by the American College of Rheumatology (ACR) in 1997.¹⁹ Childhood onset SLE was arbitrarily defined as lupus beginning before the age of 16 years, and patients with pre-menarche onset were those diagnosed with lupus before the menarche. Clinical and laboratory features were defined according to the criteria of the ACR and collected during the whole follow up period, or were derived from well documented medical records.

Only one patient had a family history of SLE. Among 64 SLE patients who underwent renal biopsy, 46 (71.9%) had diffuse or focal proliferative lesions. Neuropsychiatric manifestations other than seizures and psychosis included cerebrovascular accidents (3.6%), chorea (2.2%), cranial neuropathy (0.7%), aseptic meningitis (0.7%), and transverse myelitis (0.7%). Six patients (4.4%) had hypertension, and five (3.6%) had thyroid disease. Eight patients had overlap with Sjogren's syndrome (4), rheumatoid arthritis or juvenile chronic arthritis (3), and juvenile dermatomyositis (1). The

demographic and clinical features of the SLE group are summarised in table 1. The only significant differences between manifestations of childhood onset and adult onset subgroups were mucocutaneous manifestations, proteinuria, and proliferative lupus nephritis.

DNA isolation and genotyping

Genomic DNA was extracted from the peripheral blood using the QIAamp® DNA blood kit (Qiagen, Valencia, California, USA). Polymerase chain reaction (PCR) primers for the restriction fragment length polymorphic site in ORα were designed as reported previously: forward, 5'-CTGCCACCCT ATCTGTATCTTTCTCTATCTCC-3' and reverse, 5'-TCTTTCT CTGCCACCCTGGC-GTCGATTATCTGA-3'.¹¹ Genomic DNA (100 ng) was amplified in 50 µl of buffer solution (20 pmol of each primer, 0.2 mM dNTPs, 2 mM MgCl₂, and 2.0 U of Taq polymerase (Promega, Madison, Wisconsin, USA)). Thirty cycles of PCR were carried out as follows: denaturation at 94°C for 30 seconds, annealing at 55°C for 60 seconds, and extension at 72°C for 90 seconds. PCR products were digested using 20 U of either *PvuII* or *XbaI* restriction endonucleases (Promega) and electrophoresed on a 2.0% agarose gel. The presence of restriction sites for these endonucleases is indicated with a lower case letter (p or x, for *PvuII* or *XbaI*, respectively) and the absence of restriction site is indicated by an upper case letter (P or X).

Statistical analysis

Comparisons of the allele and genotype frequencies of patients and controls were made using the χ^2 test or Fisher's exact test as applicable. In case of multiple comparisons, the probability value (p) was corrected (p_c) for the number of comparisons made, and results were considered significant at $p_c < 0.05$. Mean differences in continuous variables were evaluated using Student's *t* test or one way analysis of variance (ANOVA) with Tukey's multiple comparison tests. Polychotomous logistic regression analysis with a generalised logit model was conducted to test for an interaction between ORα polymorphisms and clinical manifestations in the patient groups. Variables with p or $p_c < 0.05$ from univariate analyses were considered as independent

variables in the multivariate logistic regression model. Results were expressed as odds ratios (OR) with 95% confidence intervals (CI). All statistical analyses were done with SAS v8.1.

RESULTS

There was no significant difference in the allele frequency of *PvuII* or *XbaI* RFLPs between control and SLE groups. However, significantly fewer patients with childhood onset SLE had x alleles compared with the control subjects ($p = 0.003$, OR = 0.46 (95% CI, 0.27 to 0.80)) or adult onset SLE patients ($p = 0.021$, OR = 0.47 (0.25 to 0.90); table 2). Additionally, there were significantly fewer SLE patients with pre-menarche onset who had x alleles compared with either the controls (65.6% v 83.2%, $p = 0.0006$; OR = 0.39 (0.21 to 0.70)) or the post-menarche SLE group (65.6% v 82.9%, $p = 0.006$; OR = 0.40 (0.20 to 0.78)).

The Pp genotype frequency was greater in SLE patients ($p_c = 0.017$, OR = 1.79 (1.16 to 2.77)) and childhood onset SLE patients ($p_c = 0.0498$, OR = 2.24 (1.09 to 4.64)) than in the controls. The PP genotype was significantly less common in childhood onset SLE than in the controls ($p_c = 0.0045$, OR = 0 (0 to 0.63)) or adult onset cases ($p_c = 0.016$, OR = 0 (0 to 0.71); table 2). In addition, SLE patients with pre-menarche onset had a lower PP genotype frequency than the control group ($p_c = 0.021$, OR = 0 (0 to 0.81)). However, there was no difference in the genotype frequency of *PvuII* between childhood onset SLE and child control subgroups. For the *XbaI* polymorphism, SLE patients did not show any difference from the control group in the distribution of xx, Xx, and XX genotypes. In the subgroup analysis, the xx genotype was significantly less common in childhood onset SLE than in the whole control group ($p_c = 0.026$, OR = 0.42 (0.20 to 0.85)) or the child controls (51.2% v 77.1%, $p_c = 0.032$, OR = 0.31 (0.11 to 0.85)). The SLE patients with pre-menarche onset had a lower frequency of the xx genotype (43.8% v control 71.7%, $p_c = 0.0039$, OR = 0.31 (0.14 to 0.69); 43.8% v post-menarche group 71.4%, $p_c = 0.024$, OR = 0.31 (0.13 to 0.76)), and a higher frequency of Xx genotype (43.8% v control 23.1%, $p_c = 0.034$, OR = 2.58 (1.14 to 5.83)).

Table 1 Characteristics of the patients with SLE

	Total (n=137)	Adult onset (n=96)	Childhood onset (n=41)	Adult onset v childhood onset
Age at diagnosis (years)	25.8 (1.2)*	31.9 (1.2)	11.6 (0.5)	p<0.0001
Patients with pre-menarche onset	32 (23.4%)	–	32 (78.0%)	–
Duration of disease (months)	43.5 (3.1)*	39.6 (3.6)	52.7 (5.8)	p=0.054
Clinical features				
Oral ulcer	44 (32.1%)	18 (18.8%)	26 (63.4%)	p<0.0001
Discoid rash	29 (21.2%)	1 (1.0%)	28 (68.3%)	p<0.0001
Malar rash	71 (51.8%)	41 (42.7%)	30 (73.2%)	p=0.001
Photosensitivity	19 (13.9%)	7 (7.3%)	12 (29.3%)	p=0.002
Arthritis	78 (56.9%)	53 (55.2%)	25 (61.0%)	p=0.58
Serositis	36 (26.3%)	28 (29.2%)	8 (19.5%)	p=0.29
Neuropsychiatric SLE	7 (5.1%)	3 (3.1%)	4 (9.8%)	p=0.56
Laboratory findings				
Leucopenia	70 (51.1%)	51 (53.1%)	19 (46.3%)	p=0.29
Haemolytic anaemia	15 (10.9%)	13 (13.5%)	2 (4.9%)	p=0.23
Thrombocytopenia	44 (32.1%)	30 (31.3%)	14 (34.1%)	p=0.44
Proteinuria	73 (53.2%)	42 (43.8%)	31 (75.6%)	p=0.001
Proliferative lupus nephritis	46 (33.8%)	21 (21.9%)	25 (61.0%)	p=0.001
ANA	137 (100%)	96 (100%)	41 (100%)	p=1.00
Anti-dsDNA	122 (89.1%)	81 (84.4%)	41 (100%)	p=0.005
Anti-sm	20 (14.6%)	12 (12.5%)	8 (19.5%)	p=0.30
Anti-phospholipid	44 (32.1%)	29 (30.2%)	15 (36.6%)	p=0.55

Significant values in bold.
*Mean (SEM).
ANA, antinuclear antibodies; SLE, systemic lupus erythematosus.

Table 2 Allele and genotype frequencies of ORα polymorphism in controls and SLE patients

	Control (n = 268)	SLE (n = 137)	Adult onset SLE (n = 96)	Childhood onset SLE (n = 41)
<i>For PvuII</i>				
Allele P	198 (36.9%)	168 (61.3%)	81 (42.2%)	25 (30.5%)
p	338 (63.1%)	106 (38.7%)	111 (57.8%)	57 (69.5%)
Genotype PP	44 (16.4%)	15 (10.9%)	15 (15.6%)	0 (0%)††
Pp	110 (41.1%)	76 (55.5%)*	51 (53.1%)	25 (61.0%)§
pp	114 (42.5%)	46 (33.6%)	30 (31.3%)	16 (39.0%)
<i>For XbaI</i>				
Allele X	90 (16.8%)	58 (21.2%)	33 (17.2%)	25 (30.5%)
x	446 (83.2%)	216 (78.8%)	159 (82.8%)	57 (69.5%)***
Genotype XX	14 (5.2%)	10 (7.3%)	5 (5.2%)	5 (12.2%)
Xx	62 (23.1%)	38 (27.7%)	23 (24.0%)	15 (36.6%)
xx	192 (71.7%)	89 (65.0%)	68 (70.8%)	21 (51.2%)††

* $p_c = 0.0174$, OR = 1.79 (95% CI, 1.16 to 2.77) v control.
† $p_c = 0.0045$, OR = 0 (0 to 0.63) v control.
‡ $p_c = 0.016$, OR = 0 (0 to 0.71) v adult onset SLE.
§ $p_c = 0.0498$, OR = 2.24 (1.09 to 4.64) v control.
* $p = 0.003$, OR = 0.46 (0.27 to 0.80) v control.
** $p = 0.021$, OR = 0.47 (0.25 to 0.90) v adult onset SLE.
†† $p_c = 0.0255$, OR = 0.42 (0.20 to 0.85) v control.
CI, confidence interval; OR, odds ratio; SLE, systemic lupus erythematosus.

For the combination of the *PvuII* and *XbaI* polymorphisms, all combinations of genotype were observed in SLE patients, and the three major combined genotypes in the study groups were ppxx, Ppxx, and PpXx. SLE patients less often had the ppxx genotype than controls ($p_c = 0.032$, OR = 0.52 (0.32 to 0.83); fig 1). The frequency of the ppXx genotype was greater in the childhood onset SLE subgroup than in the control group or the adult onset subgroup ($p_c = 0.0009$, OR = 22.80 (3.94 to 170.36) v controls; $p_c = 0.027$, OR = 16.29 (1.83 to 371.63) v adult onset SLE; fig 1). Moreover, the same tendency was detected in SLE patients with pre-menarche onset ($p_c = 0.0009$, OR = 24.63 (3.96 to 193.51) v controls; $p_c = 0.018$, OR = 9.54 (1.51 to 75.71) v SLE patients with post-menarche onset).

When clinical manifestations in SLE patients were analysed according to *PvuII* or *XbaI* polymorphisms, oral ulcer was associated with the pp genotype ($p_c = 0.015$, OR = 2.88 (1.27 to 6.54)) and discoid rash was related to the xx genotype ($p_c = 0.032$, OR = 0.34 (0.14 to 0.86)). Age at disease onset differed significantly in SLE patients according to the presence of *PvuII* or *XbaI* polymorphisms. SLE patients with the PP genotypes (mean (SEM), 38.1 (2.9) years old) were significantly older at disease onset than the other genotypes ($p = 0.001$, v 23.8 (2.0) years in the pp genotype, v 24.6 (1.5) in the Pp genotype; table 3). The patients with the xx genotype had a later onset of SLE than those with the Xx genotype ($p = 0.025$; 28.1 (1.5) v 21.0 (1.6) years; table 3). In the childhood onset SLE subgroup, patients with the pp genotype developed disease earlier than those with the Pp genotype (at 10.3 (0.9) v 12.4 (0.4) years, $p = 0.046$). However, in the adult onset SLE subgroup, the age at disease onset did not differ according to ORα RFLPs. The distributions of the other clinical and laboratory manifestations were not significantly skewed.

To confirm the relation of ORα polymorphisms with disease onset in the SLE group, a logistic multivariate analysis was conducted (table 3). The models for *PvuII* or *XbaI* polymorphisms included a continuous variable, age at disease onset, and some dichotomous variables such as oral ulcer, discoid rash, malar rash, photosensitivity, proteinuria, proliferative lupus nephritis, and anti-dsDNA. For the *PvuII* polymorphism, the variables of oral ulcer and age at disease onset interacted significantly ($p = 0.047$). A significant difference in the age at onset between the PP and pp

genotypes was observed (adjusted OR = 1.10 (1.03 to 1.18)) under the condition of the absence of oral ulcer. When the adjusted OR for oral ulcer was calculated using first quartile, median, and third quartile age groups, there was no statistical significance. For the *XbaI* polymorphism, patients with the Xx genotype showed a younger onset than those with the xx genotype (adjusted OR = 0.95 (0.91 to 0.98)).

DISCUSSION

SLE is a multifactorial autoimmune disease, and genetic factors are thought to contribute to its pathogenesis. In human lupus studies, associations of SLE with some major histocompatibility class II alleles, complement deficiencies, and polymorphisms of Fcγ receptor genes, a complement related gene, and cytokine genes have been described. The biological actions of oestrogens are mediated through the oestrogen receptors, which function as a ligand inducible transcription factor and convey signals by binding as a complex of accessory proteins to specific DNA sequences in the promoters of oestrogen dependent genes. Thus oestrogen receptor polymorphism has been a target in the genetic study of diseases in which oestrogen may play a pathogenic role. However, although ORα polymorphism has been extensively investigated in many disorders, its association in SLE has not been fully examined. *PvuII* and *XbaI* RFLPs are representative among polymorphisms of the ORα gene and they have been reported to be associated with breast cancer, endometrial cancer, generalised osteoarthritis, bone mineral density, and lipid metabolism.^{10–16}

Previously, Liu *et al* reported the different distribution of ORα gene polymorphism in both male and female SLE patients, and showed a higher frequency of the PpXx genotype in male patients with lupus nephritis than in normal controls and female patients.¹⁷ In our study group, we examined ORα RFLPs in female patients to minimise the effect of the sex variable and did not observe a relation between renal disease and ORα polymorphism. The frequency of the ppxx genotype was lower in SLE patients than in controls, and ORα genotype distributions of adult onset SLE did not differ significantly from controls. Chang and his colleagues showed that ORβ microsatellite polymorphism was not associated with SLE.¹⁸ Whether oestrogenic effects are mediated through ORα or ORβ remains unclear, but sex hormones influence both humoral and cell mediated immune

Figure 1 Combined genotype of oestrogen receptor α polymorphism in controls and patients with systemic lupus erythematosus (SLE). For the combination of the *PvuII* and *XbaI* polymorphisms, all combinations of genotypes were observed in SLE patients and the three major combined genotypes: ppxx, Ppxx, and PpXx. SLE patients were less likely to have the ppxx genotype than controls (* $p_c=0.032$, OR=0.52 (95% CI, 0.32 to 0.83)). The frequency of the ppXx genotype was significantly higher in the childhood onset SLE subgroup than in the control group or the adult onset subgroup (** $p_c=0.0009$, OR = 22.80 (3.94 to 170.36) v controls; $p_c=0.027$, OR = 16.29 (1.83 to 371.63) v adult onset SLE). CI, confidence interval; OR, odds ratio.

response in SLE patients. There was a recent report that ORα is predominantly responsible for mediating oestradiol induced haematopoietic and B cell changes in mice.²⁰

In our study, we found that SLE patients with the Pp, pp, or Xx genotypes of ORα showed an earlier onset of disease and, in univariate analysis, childhood onset SLE patients

were more likely to have ppXx genotypes than adult onset patients. Linear regression analysis confirmed that those with the pp or Xx genotype developed disease earlier than the others. However, in multivariate analysis, there were no significant associations between ORα RFLPs and the other clinical or laboratory manifestations.

Table 3 Association between the age at disease onset and ORα polymorphism in patients with systemic lupus erythematosus

By one way analysis of variance:	PvuII polymorphism			XbaI polymorphism		
	PP	Pp	pp	XX	Xx	xx
Age (years) (mean (SEM))	38.1 (2.9)	24.6 (1.5)	23.8 (2.0)	24.0 (4.5)	21.0 (1.6)	28.1 (1.5)
p Value:		0.001			0.025	
By Tukey's test:	PP v Pp, p=0.001; PP v pp, p=0.001			Xx v xx, p=0.02		
By multivariate analysis:	Estimate	SEM	χ ²	p Value	Adjusted OR (95% CI)	
For PvuII						
PP v pp						
Age at onset	0.099	0.034	8.46	0.0036	1.10 (1.04 to 1.18)*	
Oral ulcer	2.148	1.164	3.40	0.0651	1.03 (0.91 to 1.17)†	
					3.33 (0.14 to 79.20)‡	
					1.79 (0.04 to 77.20)§	
					0.80 (0.009 to 75.20)¶	
Age at onset*oral ulcer	−0.067	0.034	3.93	0.0474	−	
Pp v pp						
Age at onset	−0.010	0.020	0.08	0.7824	0.99 (0.96 to 1.03)*	
Oral ulcer	1.163	0.461	6.36	0.0117	0.97 (0.91 to 1.04)†	
					2.30 (0.56 to 9.41)‡	
					1.85 (0.32 to 10.72)§	
					1.39 (0.15 to 12.79)¶	
Age at inset*oral ulcer	−0.024	0.020	1.39	0.2384	−	
For XbaI						
XX v xx						
Age at onset	−0.004	0.028	0.02	0.8760	0.99 (0.94 to 1.05)	
Oral ulcer	−0.594	0.375	2.51	0.1132	0.55 (0.26 to 1.15)	
Xx v xx						
Age at onset	−0.052	0.019	7.47	0.0063	0.95 (0.91 to 0.99)	
Oral ulcer	0.236	0.234	1.03	0.3131	1.27 (0.80 to 2.00)	

Significant results in bold.
*Without oral ulcer; †with oral ulcer; ‡age = 14 (1st quartile); §age = 23.2 (median); ¶age = 35.2 (3rd quartile).
CI, confidence interval; OR, odds ratio; ORα, oestrogen receptor α.

Several studies have shown the effect of OR α polymorphism on the oestrogen action. Menarche occurs earlier in girls with the Xx, xx, Pp, and pp genotypes than in those with the OR α XX or PP genotypes.¹⁴ Without hormone replacement therapy, the lumbar spine bone mineral density decreases significantly less in postmenopausal Finnish women with the pp genotype than in those with the PP and Pp genotypes.¹⁵ In addition, there was a greater increase in bone mineral density after hormone replacement in Japanese women with the pp genotype than in those with the Pp or PP genotypes.¹² Recently, it was observed that postmenopausal women with OR α IVS1-401 C/C—that is, the pp genotype—had greater increments in high density lipoprotein cholesterol after hormone replacement.¹⁶ Considering that the oestradiol level in prepubertal girls is lower than in women, and there was a skewed distribution of the pp and Xx genotypes in these studies, it may be speculated that the pp and Xx genotypes in our patients are oestrogen sensitive.

Some polymorphisms observed in SLE were previously reported to be related to disease onset. Reveille *et al* showed that early onset SLE patients (≤ 20 years old) have a high frequency of HLA-DRw8,²¹ and Manger *et al* reported that SLE patients with Fc γ IIA-R/R131 and IIA/IIIA-R/R131, F/F158 polymorphisms have a younger onset of disease.²² However, the number of early onset SLE subjects was very small (18 patients in the former study), or not mentioned. Our study included more childhood onset SLE patients than the previous studies, and an association between OR α polymorphism and disease onset was confirmed by both univariate and multivariate analyses. These results suggest that the OR α gene may be a susceptibility locus for childhood onset SLE in Korea.

The mechanism whereby the *PvuII* or *XbaI* polymorphisms in intron 1 of the OR α gene affect SLE remains unclear. Polymorphisms in the OR α gene are likely to affect the expression or activity of the receptor. The restriction sites are near the transactivating factor 1 domain of the OR α gene, which is an important portion for promoting transcription from oestrogen responsive promoters, and there is some evidence that protein expression or function can be influenced by polymorphisms in the first intron.^{23–25} Another explanation is that these polymorphisms can be in linkage disequilibrium with those of other genes.

Our study had some limitations. The number of childhood onset SLE patients was not large and some manifestations were different between the childhood onset and adult onset subgroups. Sample size is a common obstacle to polymorphism studies of a disease with low incidence. Although SLE is predominantly found in young women of reproductive age, 8–15% of patients were diagnosed in children younger than 16 years.²⁶ The overall incidence of SLE is between 2.0 and 7.6 per 100 000 per year, and that of childhood onset SLE, 0.36 to 0.6 per 100 000 per year.²⁷ However, the true prevalence of childhood onset SLE among SLE patients is unknown. The persuasive reason is that there is so far no strict or adopted definition of childhood onset SLE. The most used cut off ages are 14²⁶ or 16 years at onset of disease.²⁸ In our study, childhood onset SLE was defined as SLE beginning before the age of 16 years. With concerns about the different manifestations in the two subgroups, childhood onset SLE appears to have more frequent renal involvement, fever, and lymphadenopathy, and more severe organ involvement than adult onset disease.^{28–29} However, it is unknown whether this difference reflects age related factors, the disease itself, genetic factors, environmental factors, or a combination of these.³⁰ We therefore tried to minimise the sampling bias by using multivariate analyses, and the results of linear regression analysis were similar to those of univariate analysis.

Conclusions

OR α polymorphism was found to be associated with age at disease onset in Korean SLE patients, and its relation may indirectly support the concept that oestrogen affects the pathogenesis of SLE. To establish the relation between OR α polymorphisms and SLE firmly, further large scale studies of patients, including those with childhood onset SLE, are required in other populations.

ACKNOWLEDGEMENTS

We acknowledge the excellent technical assistance of Ji Hee Kim MSc. This work was supported partially by Annual Research Grants 2002 from Gyeongsang National University Hospital, Korea.

Authors' affiliations

Y J Lee, Department of Medicine, College of Medicine, Gyeongsang National University, Korea
K S Shin, Department of Paediatrics, College of Medicine, Cheju National University, Korea
S W Kang, Department of Medicine, College of Medicine, Chungnam National University, Korea
C K Lee, **B Yoo**, University of Ulsan College of Medicine, Ulsan, Korea
H S Cha, **E M Koh**, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Sungkyunkwan, Korea
S J Yoon, **J Lee**, Department of Preventive Medicine, College of Medicine, Korea University, Korea

REFERENCES

- Walker SE. The importance of sex hormones in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. *Dubois' lupus erythematosus*, 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2002:307–18.
- Carlsten H, Tarkowski A. Histocompatibility complex gene products and exposure to oestrogen: two independent disease accelerating factors in murine lupus. *Scand J Immunol* 1993;**38**:341–7.
- Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. *Arthritis Rheum* 1999;**42**:328–37.
- Evans MJ, MacLaughlin S, Marvin RD, Abdou NI. Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures. *Clin Immunol Immunopathol* 1997;**82**:258–62.
- Furukawa F, Lyons MB, Lee LA, Coulter SN, Norris DA. Estradiol enhances binding to cultured human keratinocytes of antibodies specific for SS-A/Ro and SS-B/La. Another possible mechanism for estradiol influence of lupus erythematosus. *J Immunol* 1988;**141**:1480–8.
- Wilder RL, Elenkov IJ. Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? *Ann NY Acad Sci* 1999;**876**:14–31.
- Rider V, Jones S, Evans M, Bassiri H, Afsar Z, Abdou NI. Oestrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. *J Rheumatol* 2001;**28**:2644–9.
- Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. *Ann Intern Med* 1995;**122**:430–3.
- Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. *Arthritis Rheum* 1997;**40**:804–8.
- Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. *Hum Genet* 1994;**94**:665–70.
- Ushiyama T, Ueyama H, Inoue K, Nishioka J, Ohkubo I, Hukuda S. Estrogen receptor gene polymorphism and generalized osteoarthritis. *J Rheumatol* 1998;**25**:134–7.
- Kurabayashi T, Tomita M, Matsushita H, Yahata T, Honda A, Takakuwa K, et al. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. *Am J Obstet Gynecol* 1999;**180**:1115–20.
- Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A, Baron JA. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. *Carcinogenesis* 2000;**21**:623–7.
- Stavrou I, Zois C, Ioannidis JP, Tsatsoulis A. Association of polymorphisms of the estrogen receptor alpha gene with the age of menarche. *Hum Reprod* 2002;**17**:1101–5.
- Salmen T, Heikkinen AM, Mahonen A, Kroger H, Komulainen M, Saarikoski S, et al. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. *J Bone Miner Res* 2000;**15**:315–21.

- 16 **Herrington DM**, Howard TD, Hawkins G, Reboussin DM, Xu J, Zheng SL, *et al*. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. *N Engl J Med* 2002;**346**:967–74.
- 17 **Liu ZH**, Cheng ZH, Gong RJ, Liu H, Liu D, Li LS. Sex differences in estrogen receptor gene polymorphism and its association with lupus nephritis in Chinese. *Nephron* 2002;**90**:174–80.
- 18 **Chang M**, Lubahn DB, Hoffman RW. DNA microsatellite markers for estrogen receptor-beta are not associated with systemic lupus erythematosus. *J Rheumatol* 2001;**28**:924–5.
- 19 **Hochberg MC**. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;**40**:1725.
- 20 **Thurmond TS**, Murante FG, Staples JE, Silverstone AE, Korach KS, Gasiewicz TA. Role of estrogen receptor alpha in hematopoietic stem cell development and B lymphocyte maturation in the male mouse. *Endocrinology* 2000;**141**:2309–18.
- 21 **Reveille JD**, Schrohenloher RE, Acton RT, Barger BO. DNA analysis of HLA-DR and DQ genes in American blacks with systemic lupus erythematosus. *Arthritis Rheum* 1989;**32**:1243–51.
- 22 **Manger K**, Repp R, Jansen M, Geisselbrecht M, Wassmuth R, Westerdal NA, *et al*. Fc γ receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. *Ann Rheum Dis* 2002;**61**:786–92.
- 23 **Laurie CC**, Stam LF. The effect of an intronic polymorphism on alcohol dehydrogenase expression in *Drosophila melanogaster*. *Genetics* 1994;**138**:379–85.
- 24 **An P**, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, *et al*. Modulating influence on HIV/AIDS by interacting RANTES gene variants. *Proc Natl Acad Sci USA* 2002;**99**:10002–7.
- 25 **Dupont A**, Fontana P, Bachelot-Loza C, Reny JL, Bieche I, Desvard F, *et al*. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. *Blood* 2003;**101**:1833–40.
- 26 **Font J**, Cervera R, Espinosa G, Pallares L, Ramos-Casals M, Jimenez S, *et al*. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. *Ann Rheum Dis* 1998;**57**:456–9.
- 27 **Petty RE**, Cassidy JT. Systemic lupus erythematosus. In: Petty RE, Cassidy JT. *Textbook of pediatric rheumatology*, 4th ed. Philadelphia: WB Saunders Co, 2001:397–449.
- 28 **Tucker LB**, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. *Br J Rheumatol* 1995;**34**:866–72.
- 29 **Meislin AG**, Rothfield N. Systemic lupus erythematosus in childhood. *Pediatrics* 1989;**83**:235–9.
- 30 **Sandborg CI**. Childhood systemic lupus erythematosus and neonatal lupus syndrome. *Curr Opin Rheumatol* 1998;**10**:481–7.